| Eligibility |
Inclusion Criteria:
- 18-75 years old, male or female;
- Patients diagnosed as CD20-positive diffuse large B-cell lymphoma after
histopathological or cytological examination and untreated;
- ECOG score = 2 when enrolled;
- Echocardiography measured LVEF = 50%;
- The laboratory indicators during the screening period shall meet the following
criteria:
White blood cell count (WBC) = 4.0 × 109/L or the lower limit of normal of the local
laboratory; patients with bone marrow invasion, WBC = 3.0 × 109/L; Absolute neutrophil
count (ANC) = 2.0 × 109/L or the lower limit of normal of the local laboratory; in the
patients with bone marrow invasion, ANC = 1.5 × 109/L; Hemoglobin (HB) = 90 g/L; in the
patients with bone marrow invasion, HB = 80 g/L; Platelets (PLT) = 100 × 109/L; in the
patients with bone marrow invasion, PLT = 75 × 109/L; Total bilirubin = 1.5 times upper
limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
= 2.5 × ULN; Alkaline phosphatase = 1.5 × ULN in the patients without bone marrow invasion;
Serum creatinine level = 1.5 × ULN;
- Patients having at least one two-dimensional measurable lesion as the basis for
evaluation: for intra-nodal lesions, =1.5 cm in the long diameter and =1.0 cm in the
short diameter; for extra-nodal lesions, =1.0 cm in the long diameter;
- Patients with lymphoma International Prognostic Index (IPI) score of 0-2, with stage I
to IV;
- Female at the childbearing age who show negative in the pregnancy test, and agree to
take effective contraceptive measures during the study period and within 12 months
after the last dose; male patients who agree to take effective contraceptive measures
during the study period and within 3 months after the last dose;
- Patients with the expected survival period of greater than 6 months;
- Patients voluntary to sign the Informed Consent Form.
Exclusion Criteria:
- Patients with primary central nervous system lymphoma and secondary central nervous
system invasion, gray zone lymphoma between Burkitt and DLBCL, gray zone lymphoma
between DLBCL and HL, primary mediastinal DLBCL, primary exudative lymphoma,
plasmablastic lymphoma, primary skin DLBCL, ALK-positive DLBCL or transformed
lymphoma;
- Patients with double hit (BCL-2 and c-MYC gene rearrangement) or triple hit (BCL-2,
BCL-6 and c-MYC gene rearrangement) diffuse large B-cell lymphoma diagnosed by the
FISH test method; or patients with the pathological immunohistochemical test results
as follows: BCL-2 =70% positive and c-MYC=40% positive and tumor cells judged to be
the source of germinal center according to Han's evaluation criteria but without exact
FISH test result;
- Patients with history of malignant tumors other than cutaneous squamous cell
carcinoma, cutaneous basal cell carcinoma and cervical carcinoma in situ within 5
years prior to enrollment;
- Patients with major surgery (excluding diagnostic surgery) within 2 months prior to
enrollment;
- Patients treated for non-Hodgkin's lymphoma:
Chemotherapy and immunotherapy; Radiotherapy or local radiotherapy for DLBCL; Monoclonal
antibody therapy (including Rituxan® and biosimilars of Rituxan®) Surgery (except biopsy);
- Patients previously receiving cytotoxic drugs or anti-CD20 antibodies to treat other
diseases (e.g. rheumatoid arthritis);
- Patients receiving any monoclonal antibody within 3 months prior to enrollment;
- Patients who participated in other clinical trials and used other trial-related drugs
within 3 months prior to enrollment;
- Those vaccinated within 1 month prior to enrollment;
- Those receiving hematopoietic cytokines, e.g. granulocyte colony-stimulating factor
(G-CSF) within 2 weeks prior to enrollment;
- Those with the maximum dose of >100mg Prednisone Acetate Tablets or equivalent
cortisols for more than 5 days for the purpose of controlling lymphoma, or with the
daily dose of >30mg Prednisone Acetate Tablets or equivalent cortisols for more than
10 days for the other purposes. For the patients with daily dose of =30mg Prednisone
Acetate Tablets or equivalent cortisols, there shall be written record on stable use
of pre-randomization dose for at least 4 weeks;
- Patients with peripheral nervous system or central nervous system disorder;
- Patients with suspected active or latent tuberculosis;
- Patients with known uncontrolled active bacterial, viral, fungal, mycobacterial,
parasitic or other infections (excluding nail bed fungal infection) or with any
significant systemic infection event that requires intravenous antibiotic treatment or
hospitalization (except for neoplastic fever) within 4 weeks prior to enrollment;
- HIV antibody positive;
- HCV antibody positive;
- HBV infection: (1) HBsAg positive, or (2) HBsAg negative, HBcAb positive and HBV DNA >
1 × 103
- Patients with complicated other diseases that might restrict the patients from
participation in the clinical trial in the opinion of the investigator, including but
not limited to:
Cardiovascular disease: congestive heart failure (NYHA Class III-IV), unstable angina,
poorly controlled arrhythmias, poorly controlled hypertension or hypotension or myocardial
infarction in the past 6 months; Severe mental illness; Gastric ulcer, intestinal
infarction or gastrointestinal perforation (except for ones caused by primary disease);
Pulmonary diseases (asthma, interstitial lung disease or severe obstructive pulmonary
disease); Poorly controlled diabetes.
- Patients with contraindication to any drug in the CHOP chemotherapy regime;
- Patients with allergy constitution or known to be allergic to the active ingredient,
excipient or rodent product or xenogeneic protein of any drug contained in this
clinical trial (including the CHOP regime);
- Patients unsuitable for enrollment due to alcohol or drug abuse in the opinion of the
investigator;
- Female in the pregnancy or breast-feeding period;
- Those unsuitable to participate in the clinical trial in the opinion of the
investigator.
|
